Clinical Implication of ApoB (12669G/A) Gene Polymorphism and Risk of Cardio Vascular Disease in Indian Population
Background: Cardiovascular disease is rising day by day due to having high fat diet and due to genetic alterations. Materials & Methods: Study included 70 CVD patients and their peripheral blood samples were collected for genotyping by venipuncture under aseptic condition in EDTA vials (2ml) as well as in serum vials (3ml) for biochemical parameters. Genomic DNA extraction was done by phenol chloroform method from blood samples collected in EDTA vials from cases as well as controls for genotype study. Results: The difference of genotype between cases and controls was found to be significant (p=0.0003). Study observed that high percentage of GA 29 (41.4%) and AA 8 (11.4%) genotype was found in patients compared to controls GA 10 (20%) and AA 0 (0%) while lower GG 33 (47.2%) genotype in patients compared to control GG 40 (80%) genotype. Compared to the GG genotype, the OR 3.51 (1.49-8.25) and 20.55 (1.14-369.6) for the heterozygous GA and homozygous AA genotypes were estimated, suggesting a possible dominant effect of Apo B polymorphism on CVD risk. In smokers, compared to the GG genotype, the OR 2.19 (0.69-6.88) and 1.71 (0.29-9.87) for the heterozygous GA and homozygous AA genotypes. In alcoholism, compared to the GG genotype, the OR 2.66 (0.93-7.57) and 8.4 (0.92-76.19) for the heterozygous GA and homozygous AA genotypes. Patients with mutant homozygous AA, heterozygous GA genotypes showed 123.3+14.34 (mg/dl) and 76.92+24.09 Apo B level in CVD patients compared to wild type GG homozygous genotypes were 70.82+17.12. Conclusion: It was observed that Apo B gene polymorphism and smoking behaviour found to be associated with increased risk of CVD in Indian population.
2. N. Brucker, M. F. Char˜ao, A. M. Moro et al, “Atherosclerotic process in taxi drivers occupationally exposed to air pollution and co-morbidities,” Environmental Research, vol. 131, pp. 31–38, 2014.
3. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5: 150–9.
4. Sniderman AD, Williams K, Contois JH, Moonroe HM, McQueen MJ, de Graaf J, Furberg CD. A metaanalysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011; 4: 337–45.
5. Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, Hu FB. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004; 27: 1991–7.
6. Beekman M, Heijmans BT, Martin NG, Pedersen NL, Whitfi eld JB, De- Faire U, van Baal GC, Snieder H,Vogler GP, Slagboom PE, Boomsma DI. Heritabilities of apolipoprotein and lipid levels in three countries. Twin Res 2002; 5: 87–97.
7. Chiodini BD, Barlera S, Franzosi MG, Beceiro VL, Introna M, Tognoni G. APO B gene polymorphisms and coronary artery disease: a meta-analysis. Atherosclerosis 2003; 167: 355 – 66.
8. Monsalve MV, Young R, Jobsis J, Wiseman SA, Dhamu S, Powell JT, Greenhalgh RM, Humphries SE. DNA polymorphisms of the gene for apolipoprotein B in patients with peripheral arterial disease. Atherosclerosis 1988; 70: 123–9.
9. Nabel E G (2003). Cardiovascular disease. N Engl J Med 349, 60-72.
10. Frossard P M, Obineche E N, Lestringant G G (1999). Association of an apolipoprotein B gene marker with essential hypertension. Hypertension 33, 1052-1056.
11. Herbert PN, Assmann G, Gotto Jr AM, Fredrickson DS. Familial lipoprotein deficiency: a beta lipoproteinemia, hypobetalipoproteinemia, and Tangier disease. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, editors. The Metabolic Basis of Inherited Disease. 5th ed. New York, NY: McGraw-Hill; 1983. p. 672–712.
12. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, editors. The metabolic basis of inherited disease. 5th ed. New York, NY: McGraw-Hill; 1983. p. 672–712.
13. Carlsson P, Darnfors C, Olofsson SO, Bjursell G. Analysis of the human apolipoprotein B gene; complete structure of the B-74 region. Gene.1986;49:29–55.
14. Young DS, Pestaner LC, Gibberman V. Effects of drugs on clinical laboratory tests. Clin Chem. 1975;21:1D–432.
15. Padmaja N, Kumar MR, Adithan C. Association of polymorphisms in apolipoprotein A1 and apolipoprotein B genes with lipid profile in Tamilian population. Indian Heart J. 2008;61(1): 51–4.
16. Gallegos-Arreola MP, Valdez Y, Zu´n˜iga-Corona M, Figuera LE, Arnaud-Lopez L, Robles-Cervantes JA, et al. Association between the Xba I polymorphism of APOB gene and plasma lipid level in Mexican patients with coronary artery disease. Asia Pac J Clin Nutr. 2012;21(2):312.
17. Cavalli SA, Hirata MH, Salazar LA, Diament J, Forti N, Giannini SD, et al. Apolipoprotein B gene polymorphisms: prevalence and impact on serum lipid concentrations in hypercholesterolemic individuals from Brazil. Clin Chim Acta. 2000;302 (1):189–203.
18. Chiodini B D, Barlera S, Franzosi M G, et al. (2003). APO B gene polymorphisms and coronary artery disease: a meta-analysis. Atherosclerosis, 167, 355-366.